Form 4: Apellis Officer Sells Shares for Tax Withholding

Apellis Pharmaceuticals' Chief Business & Strategy Officer, Mark DeLong, sold 3,371 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mark DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, Inc. (APLS), reported a transaction.
• On January 22, 2026, DeLong disposed of 3,371 shares of Apellis common stock.
• The shares were sold at a price of $21.7654 per share.
• This sale was conducted to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that vested on January 21, 2026.
• Following this transaction, DeLong beneficially owns 78,353 shares of Apellis common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares by an officer to cover tax withholding obligations upon the vesting of Restricted Stock Units, which is a common and expected practice and does not reflect a discretionary investment decision.

Positives

• Vesting of Restricted Stock Units (RSUs) indicates a component of executive compensation being realized.

Negatives

• No direct negatives identified from this routine tax-related transaction.

Future Outlook

This Form 4 filing reports a planned future transaction related to executive compensation and tax obligations, not the company's operational future outlook.

Industry Context

This is a routine insider transaction related to executive compensation and tax planning, common across publicly traded companies, and does not provide specific insights into broader industry trends for pharmaceuticals.

Comparison to Industry Standards

• The sale of shares to cover tax withholding upon RSU vesting is a standard and common practice for executives in publicly traded companies across all industries, including pharmaceuticals. It aligns with typical executive compensation and tax planning strategies.

Stakeholder Impact

• Minimal impact on shareholders as it represents a routine, non-discretionary sale of a small number of shares relative to the company's total outstanding stock.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares by an executive to cover tax withholding obligations associated with RSU vesting. This is a common and expected event and does not signal a change in the company's fundamentals or the executive's confidence in the company, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, insider trading, Form 4, stock sale, executive compensation, RSU, tax withholding